Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Nepal and Afghanistan show how abrupt aid cuts can unravel essential care

24

Mar 2026

Nepal and Afghanistan show how abrupt aid cuts can unravel essential care

Abrupt cuts to external health aid can destabilize multiple essential services simultaneously in fragile, donor-dependent settings, as illustrated by Nepal and Afghanistan. The paper argues that donor withdrawal is not just a resilience test, but also an ethical and governance issue that should be managed through “transition discipline.”

Moderate coffee intake may lower heart failure risk

24

Mar 2026

Moderate coffee intake may lower heart failure risk

A systematic review and dose-response meta-analysis of seven prospective cohorts found that drinking 2 to 4 cups of coffee a day was associated with a modestly lower risk of incident heart failure. The lowest estimated risk appeared at 1 to 2 cups daily, although the evidence for a true non-linear J-shaped pattern was suggestive rather than definitive.

Wholegrain rye changes gut bacteria and lowers inflammation in obesity trial

24

Mar 2026

Wholegrain rye changes gut bacteria and lowers inflammation in obesity trial

In a 12-week randomized trial, replacing refined wheat with wholegrain rye in a calorie-restricted diet did not produce greater weight loss in adults with overweight or obesity. Wholegrain rye did, however, lower C-reactive protein and alter gut microbiota and short-chain fatty acids in ways that may have positive cardiometabolic implications.

Deepfake X-rays can deceive radiologists and AI systems

24

Mar 2026

Deepfake X-rays can deceive radiologists and AI systems

Neither radiologists nor multimodal large language models (LLMs) are able to easily distinguish artificial intelligence (AI)-generated "deepfake" X-ray images from authentic ones, according to a study published today in Radiology, a journal of the Radiological Society of North America (RSNA).

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.